Table 1 Clinical characteristic of study population

FFAs (mmol/l)

0.27 (0.21, 0.32)

0.46 (0.42, 0.49)

0.65 (0.59, 0.72)

1.01 (0.88, 1.28)

-

 Age (y)

63 ± 13

60 ± 10.4

60 ± 10.4

62 ± 12

0.021

 Male (%)

65.5

67.9

70.6

66.8

NS

Risk factors

 SBP (mmHg)

141 ± 24

133 ± 16

134 ± 21

124 ± 20

NS

 DBP (mmHg)

82 ± 11

79 ± 11

82 ± 15

75 ± 11

NS

 HR (bpm)

72 ± 7

74 ± 15

75 ± 8

74 ± 14

0.01

 Smoking (%)

33.8

51.9

51.3

49.7

0.005

 Hypertension (%)

67.7

69.3

65.4

57.4

0.043

 Diabetes mellitus (%)

26.9

30.3

31.3

29.6

NS

 Hyperlipidemia (%)

58.7

62.4

70.2

66.4

0.048

Laboratory parameter

 TC (mmol/l)

4.04 ± 0.86

4.28 ± 1.04

4.78 ± 1.56

4.3 ± 0.88

<0.001

 HDL-C (mmol/l)

1 ± 0.2

1.05 ± 0.2

0.99 ± 0.21

1 ± 0.2

NS

 LDL-C (mmol/l)

2.5 ± 0.92

2.73 ± 0.83

2.93 ± 0.8

2.75 ± 0.7

<0.001

 Lp (a) (mg/l)

131 (67, 246)

78 (37, 312)

125 (61, 202)

136 (56, 209)

NS

 TG (mmol/l)

1.63 ± 0.92

1.96 ± 1.37

2.35 ± 1.45

2.01 ± 1.6

<0.001

 FBG (mmol/l)

5.96 ± 1.7

6.3 ± 2.6

7 ± 2.7

6.5 ± 3.3

<0.001

 WBC (×10⁹)

7.5 ± 3.7

6.9 ± 2.2

8.1 ± 3.1

9.24 ± 3.2

<0.001

 cTnT(ng/ml)

0.02 (0.003, 0.49)

0.07 (0.007, 2.84)

0.28 (0.01, 6.65)

1.72 (0.05, 15.1)

<0.001

 hs-CRP (mg/l)

2.64 (0.58, 6.2)

2.42 (1.43, 3.83)

3.4 (1.16, 9.18)

2.43 (0.94, 11.7)

<0.001

 CK-MB (U/l)

13 (8.5, 18.5)

13 (9, 26)

18 (11, 49)

31 (12, 102.8)

<0.001

 eGFR (ml/min/1.73 m²)

93.4 ± 28.9

95.3 ± 20.2

98.2 ± 19.8

96.8 ± 30.8

NS

 Number of vessel

2.2 ± 0.6

2.13 ± 0.9

2.24 ± 0.74

1.97 ± 0.86

NS

 Maximal stenosis (%)

78.3 ± 16.8

81.2 ± 20

83.3 ± 18

84.6 ± 19.1

<0.001

 Gensini score

22.9 ± 18

29.9 ± 28

37.9 ± 30

43.7 ± 41

0.001

 ACS n (%)

72 (8.1)

103 (11.5)

135 (15.1)

176 (19.7)

<0.001

 STEMI n(%)

11 (1.2)

31 (3.5)

60 (6.7)

92 (10.3)

<0.001

 β-Blocker n (%)

43 (19.2)

43 (19.8)

39 (17.1)

36 (16.3)

NS

 Aspirin n (%)

215 (96.3)

209 (95.7)

207 (91)

211 (94.5)

NS

 Stent implantation n (%)

60 (27.1)

62 (28.2)

68 (29.7)

70 (31.4)

NS